NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Synthetic Biologics, Inc (AMEX: SYN)

 
SYN Technical Analysis
1.5
As on 31st Oct 2017 SYN Share Price closed @ 0.82 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.71 & Sell for SHORT-TERM with Stoploss of 0.82 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

SYN Share Price

Open 0.81 Change Price %
High 0.82 1 Day 0.02 2.50
Low 0.79 1 Week 0.00 0.00
Close 0.82 1 Month -0.06 -6.82
Volume 506628 1 Year -0.76 -48.10
52 Week High 1.60 | 52 Week Low 0.41
 
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
NGD 3.29 -6.80%
RBY 0.03 -70.00%
LODE 0.12 -7.69%
PBTH 8.23 0.37%
GGR 0.02 100.00%
VTG 0.05 -16.67%
SYRG 8.13 0.87%
GSX 0.02 0.00%
SHZ 0.10 -16.67%
 
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
 
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
LBY 6.84 -25.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
 
 
SYN
Daily Charts
SYN
Intraday Charts
Whats New @
Bazaartrend
SYN
Free Analysis
 
SYN Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE0.85
RESISTANCE0.84
SUPPORT0.80
SUPPORT0.79
SUPPORT0.00
SUPPORT0.00
 
SYN Target for Month November
4th UP TARGET1.19
3rd UP TARGET1.07
2nd UP TARGET1
1st UP TARGET0.92
1st DOWN TARGET0.72
2nd DOWN TARGET0.64
3rd DOWN TARGET0.57
4th DOWN TARGET0.45
 
SYN Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
SYN Target for Year 2020
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
SYN Other Details
Segment EQ
Market Capital 85700304.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
SYN Address
SYN
155 Gibbs Street
Suite 412
Rockville, MD 20850
United States
Phone: 734-332-7800
Fax: 734-332-7878
 
SYN Latest News
 
Your Comments and Response on Synthetic Biologics, Inc
 
SYN Business Profile
Synthetics Biologics, Inc., a biotechnology company, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases. The company’s product candidates include Trimesta, which has completed phase II clinical trials for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis; SYN-010 that is in preclinical stage for the treatment of constipation-predominant irritable bowel syndrome; SYN-004, which is in preclinical stage for the treatment of clostridium difficile infection prevention; SYN-005 that is in preclinical stage for the treatment of pertussis; SYN-001, which is in discovery stage for the treatment of acinetobacter infection; and SYN-007 that is in discovery stage for the treatment of irritable bowel syndrome. It has a sublicense agreement with Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the United States, Canada, and Japan. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetics Biologics, Inc. in February 2012. Synthetics Biologics, Inc. was founded in 2001 and is based in Rockville, Maryland.
 
© 2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service